0.30% -0.000099

Nls Pharmaceutics Ag (NLSPW)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Nls Pharmaceutics Ag

Healthcare (1170)

Biotechnology (665)

41 44 512 21 50

The Circle 6, Zurich

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NLSPW's Discussions on Twitter

Vergleichen Sie NLSPW mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NLSPW Nls Pharmaceutics Ag	0.0325	0	0	0	0	0.00
ONC Beone Medicines Ltd Adr	258.27	26.01B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.85	114.30B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.3499	41.83M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	83.98	6.29B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	484.93	63.90B	14.09B	4.50B	2.96B	39.28

Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten

Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)

Es liegen keine Finanzdaten für Nls Pharmaceutics Ag (NLSPW) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Nls Pharmaceutics Ag (NLSPW)

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Vergleichen Sie NLSPW mit anderen Aktien

Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten

Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia

NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com India

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - Seeking Alpha

NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World

Narcolepsy Therapeutics Market Expected to Reach USD 7,852.93 Million by 2034, Growing at a CAGR of 7.5% As... - WhaTech

Narcolepsy Market: Epidemiology, Therapies, Companies, - openPR.com

Pre-market Movers: STSS, THRD, PTN, VRAX... - RTTNews

Press Release Distribution & PR Platform - ACCESS Newswire

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com

NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks

Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - marketscreener.com

Kadimastem Ltd. announced that it expects to receive ILS 2 million in funding. - marketscreener.com

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire

NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire

NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com

NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com

NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India

NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK

NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo Finance

Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com

NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa

NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com

NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire

AEX-2 increases total wake duration in mouse model - BioWorld Online

NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire

NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa

NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com

Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online

NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance

NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire

NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq

Is NLSP’s price to cash per share ratio a concern for investors? - US Post News

NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - Marketscreener.com

NLS and Kadimastem to merge, aim for diabetes care innovation - Investing.com

Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NLSPW